The antidepressant-like effects of combination buprenorphine/naltrexone in the novelty-induced hypophagia task in mice

Sarah Bailey, Abdulrahman Mohammed I Almatroudi, Christopher Bailey, Stephen Husbands

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Abstract

Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). Buprenorphine is a partial mu-opioid receptor agonist and a kappa-antagonist, while naltrexone is a non-selective opioid antagonist. We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist that was non-sedating and non-rewarding in mice. Here, we report the effects of this combination treatment on depression-related behaviour. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine alone (1 mg/kg), naltrexone alone (1 mg/kg), buprenorphine/naltrexone combination (1 mg/kg), norBNI (10mg/kg) or fluoxetine (20 mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (5, 54) =8.5, P<0.001) but not consumption (F (5, 54) =1, P=0.4). The combination of buprenorphine/naltrexone produced antidepressant-like effects, significantly reducing the latency to drink in the novel cage, compared with controls. Interestingly, the effects of the combination treatment were similar to naltrexone alone. We have previously shown that mixed mu-/kappa-opioid receptor antagonists have antidepressant and anxiolytic potential (Casal-Dominguez et al. 2013 J Psychopharm 27:192-202). We are investigating whether combination buprenorphine/ naltrexone may also have anxiolytic potential in mice.
Original languageEnglish
Title of host publicationNeuroscience Meeting Planner
Subtitle of host publicationSociety for Neuroscience
Place of PublicationOnline
Publication statusPublished - 2014
EventSociety for Neuroscience - Wasihngton DC, USA United States
Duration: 15 Nov 2014 → …

Conference

ConferenceSociety for Neuroscience
CountryUSA United States
CityWasihngton DC
Period15/11/14 → …

Fingerprint

Buprenorphine
Naltrexone
Antidepressive Agents
kappa Opioid Receptor
Narcotic Antagonists
mu Opioid Receptor
Anti-Anxiety Agents
Fluoxetine
Analysis of Variance
Milk
Depression
Pharmaceutical Preparations

Keywords

  • Depression

Cite this

The antidepressant-like effects of combination buprenorphine/naltrexone in the novelty-induced hypophagia task in mice. / Bailey, Sarah; Almatroudi, Abdulrahman Mohammed I; Bailey, Christopher; Husbands, Stephen.

Neuroscience Meeting Planner: Society for Neuroscience. Online, 2014.

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Bailey, S, Almatroudi, AMI, Bailey, C & Husbands, S 2014, The antidepressant-like effects of combination buprenorphine/naltrexone in the novelty-induced hypophagia task in mice. in Neuroscience Meeting Planner: Society for Neuroscience. Online, Society for Neuroscience, Wasihngton DC, USA United States, 15/11/14.
@inproceedings{d03fb4090c484cb48ebb6cc3d0c28dc8,
title = "The antidepressant-like effects of combination buprenorphine/naltrexone in the novelty-induced hypophagia task in mice",
abstract = "Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). Buprenorphine is a partial mu-opioid receptor agonist and a kappa-antagonist, while naltrexone is a non-selective opioid antagonist. We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist that was non-sedating and non-rewarding in mice. Here, we report the effects of this combination treatment on depression-related behaviour. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine alone (1 mg/kg), naltrexone alone (1 mg/kg), buprenorphine/naltrexone combination (1 mg/kg), norBNI (10mg/kg) or fluoxetine (20 mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (5, 54) =8.5, P<0.001) but not consumption (F (5, 54) =1, P=0.4). The combination of buprenorphine/naltrexone produced antidepressant-like effects, significantly reducing the latency to drink in the novel cage, compared with controls. Interestingly, the effects of the combination treatment were similar to naltrexone alone. We have previously shown that mixed mu-/kappa-opioid receptor antagonists have antidepressant and anxiolytic potential (Casal-Dominguez et al. 2013 J Psychopharm 27:192-202). We are investigating whether combination buprenorphine/ naltrexone may also have anxiolytic potential in mice.",
keywords = "Depression",
author = "Sarah Bailey and Almatroudi, {Abdulrahman Mohammed I} and Christopher Bailey and Stephen Husbands",
year = "2014",
language = "English",
booktitle = "Neuroscience Meeting Planner",

}

TY - GEN

T1 - The antidepressant-like effects of combination buprenorphine/naltrexone in the novelty-induced hypophagia task in mice

AU - Bailey, Sarah

AU - Almatroudi, Abdulrahman Mohammed I

AU - Bailey, Christopher

AU - Husbands, Stephen

PY - 2014

Y1 - 2014

N2 - Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). Buprenorphine is a partial mu-opioid receptor agonist and a kappa-antagonist, while naltrexone is a non-selective opioid antagonist. We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist that was non-sedating and non-rewarding in mice. Here, we report the effects of this combination treatment on depression-related behaviour. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine alone (1 mg/kg), naltrexone alone (1 mg/kg), buprenorphine/naltrexone combination (1 mg/kg), norBNI (10mg/kg) or fluoxetine (20 mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (5, 54) =8.5, P<0.001) but not consumption (F (5, 54) =1, P=0.4). The combination of buprenorphine/naltrexone produced antidepressant-like effects, significantly reducing the latency to drink in the novel cage, compared with controls. Interestingly, the effects of the combination treatment were similar to naltrexone alone. We have previously shown that mixed mu-/kappa-opioid receptor antagonists have antidepressant and anxiolytic potential (Casal-Dominguez et al. 2013 J Psychopharm 27:192-202). We are investigating whether combination buprenorphine/ naltrexone may also have anxiolytic potential in mice.

AB - Antagonists at kappa-opioid receptors have been proposed as novel antidepressants. The standard high-affinity, selective kappa-antagonists have a long lasting duration of action which potentially limits their use (Carroll and Carlezon 2013. J Med Chem 56: 2178-2195). Buprenorphine is a partial mu-opioid receptor agonist and a kappa-antagonist, while naltrexone is a non-selective opioid antagonist. We have previously shown that the combination of buprenorphine (1mg/kg) with naltrexone (1mg/kg) produced a functional short-acting kappa-antagonist that was non-sedating and non-rewarding in mice. Here, we report the effects of this combination treatment on depression-related behaviour. Adult male CD-1 mice (8-9 weeks) were used. For novelty-induced hypophagia, mice were individually housed and trained for 3 days to consume condensed milk. On test days, mice were injected intraperitoneally (10 ml/kg) with saline, buprenorphine alone (1 mg/kg), naltrexone alone (1 mg/kg), buprenorphine/naltrexone combination (1 mg/kg), norBNI (10mg/kg) or fluoxetine (20 mg/kg) one hour prior to testing behaviour. The latency to drink and consumption were recorded in the home cage (day 4) and in the novel cage (day5). One-way ANOVA, revealed that there was a significant effect of drug treatment on the latency to drink in the novel cage (F (5, 54) =8.5, P<0.001) but not consumption (F (5, 54) =1, P=0.4). The combination of buprenorphine/naltrexone produced antidepressant-like effects, significantly reducing the latency to drink in the novel cage, compared with controls. Interestingly, the effects of the combination treatment were similar to naltrexone alone. We have previously shown that mixed mu-/kappa-opioid receptor antagonists have antidepressant and anxiolytic potential (Casal-Dominguez et al. 2013 J Psychopharm 27:192-202). We are investigating whether combination buprenorphine/ naltrexone may also have anxiolytic potential in mice.

KW - Depression

M3 - Conference contribution

BT - Neuroscience Meeting Planner

CY - Online

ER -